AU3129993A - Localized oligonucleotide therapy - Google Patents

Localized oligonucleotide therapy

Info

Publication number
AU3129993A
AU3129993A AU31299/93A AU3129993A AU3129993A AU 3129993 A AU3129993 A AU 3129993A AU 31299/93 A AU31299/93 A AU 31299/93A AU 3129993 A AU3129993 A AU 3129993A AU 3129993 A AU3129993 A AU 3129993A
Authority
AU
Australia
Prior art keywords
oligonucleotide therapy
localized
localized oligonucleotide
therapy
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31299/93A
Inventor
Jean-Luc Dekeyser
Elazer Edelman
Robert S. Langer
Robert D. Rosenberg
Michael Simons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of AU3129993A publication Critical patent/AU3129993A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
AU31299/93A 1991-11-08 1992-11-05 Localized oligonucleotide therapy Abandoned AU3129993A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US792146 1985-10-28
US79214691A 1991-11-08 1991-11-08
US85541692A 1992-03-18 1992-03-18
US855416 1992-03-18

Publications (1)

Publication Number Publication Date
AU3129993A true AU3129993A (en) 1993-06-07

Family

ID=27121241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31299/93A Abandoned AU3129993A (en) 1991-11-08 1992-11-05 Localized oligonucleotide therapy

Country Status (2)

Country Link
AU (1) AU3129993A (en)
WO (1) WO1993008845A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
BR9405707A (en) * 1993-01-07 1996-08-06 Univ Jefferson Anti-sense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US6323184B1 (en) * 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
EP0723440B1 (en) * 1993-10-15 2003-01-02 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
AU2099095A (en) * 1994-03-07 1995-09-25 Immusol, Inc Ribozyme therapy for restenosis
FR2723697B1 (en) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa METHOD OF TREATING RESTENOSIS WITH GENE THERAPY
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
DK0885002T3 (en) * 1996-03-04 2011-08-22 Penn State Res Found Materials and methods for enhancing cellular internalization
US6387390B1 (en) 1998-10-05 2002-05-14 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
SI0946185T2 (en) * 1996-11-27 2010-08-31 Aventis Pharma Inc PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
PT1222266E (en) 1999-09-29 2006-07-31 Diagnocure Inc PCA3 MESSENGER RNA IN BENEFICIAL AND MALIGNAL PROSTATE TISSUES
AU4793101A (en) 2000-03-31 2001-10-15 Aventis Pharm Prod Inc Nuclear factor kb inducing factor
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
ES2427853T3 (en) 2003-02-07 2013-11-04 Diagnocure Inc. Procedure to detect prostate cancer in a sample
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
BRPI0714981A2 (en) 2006-07-28 2013-08-13 Sanofi Aventis A method of making the same comprising an inhibitor that inhibits the activity of a complex iii protein, a vehicle and a member of the tumor necrosis factor superfamily, a method for conducting an assay to determine whether a compound is an inhibitor. of tnf suppression activity of a complex iii protein and use of a compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740463A (en) * 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
AU646643B2 (en) * 1989-09-01 1994-03-03 Temple University - Of The Commonwealth System Of Higher Education Antisense oligonucleotides to C-ABL proto-oncogene
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
AU7676191A (en) * 1990-04-09 1991-10-30 American National Red Cross, The Rejuvenation compositions and methods for their use

Also Published As

Publication number Publication date
WO1993008845A1 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
AU3972893A (en) Gene therapy using the intestine
AU5457096A (en) Gene-transfer-mediated angiogenesis therapy
HK1008979A1 (en) Gene transfer-mediated angiogenesis therapy
AU3129993A (en) Localized oligonucleotide therapy
ZA9533B (en) Pentolifylline therapy
AU6092794A (en) Oxime-substituted therapeutic compounds
AU4377793A (en) Alternative receptor therapy
AU2838192A (en) Catheter
AU6386390A (en) Therapeutic necleosides
AU1480497A (en) Cancer treatment
GB9509572D0 (en) Cancer therapy
GB9307013D0 (en) Therapeutic combinations
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
GB9308166D0 (en) Cancer therapy
PH31659A (en) Therapeutic nucleotides.
GB9524942D0 (en) Drug therapy
AU6594690A (en) Therapeutic agents
GB9317146D0 (en) Therapeutic combinations
AU1175692A (en) Effluent treatment
GB9310441D0 (en) Gene therapy
AU5165993A (en) Pp14-based therapy
AU2687092A (en) Fluid treatment
AU6177190A (en) Therapeutic agents
GB9521711D0 (en) Gene therapy
GB9520433D0 (en) Gene therapy